Kornimate/medical-research-clean huggingface dataset:
a study of trs01 in subjects with active non-infectious anterior uveitis including subjects with uveitic glaucoma

Conditions: Non-infectious Anterior Uveitis; Uveitic Glaucoma

Summary: the primary objective of this study is to evaluate the efficacy and safety of trs01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma


Eligibility criteria:
inclusion criteria: * at sites in the us: male or female up to and including 75 years of age (including all pediatric age groups). at sites in the europe: male or female between 18 and 70 years of age, inclusive. * diagnosed with active non-infectious anterior uveitis with anterior chamber cell grade 2 (6-15 cells) or grade 3 (16-30 cells) in the study eye that are without any treatment or with stable medical therapy requiring further treatment. * have best corrected visual acuity (bcva) vision ≥ 65 letters in the non-study eye using early treatment diabetic retinopathy study (etdrs). exclusion criteria: * pregnant or breastfeeding females or females. * history of or active significant ocular disease in either eye. * uncontrolled intraocular pressure (iop; defined as \>27mmhg) or narrow angle glaucoma in either eye and/or are at risk of angle closure with dilating. * poor posterior view due to limitation of dilation or media opacity that limits ability to examine the posterior segment. * cancer or melanoma that is actively treated with immunotherapy. * certain clinically significant systemic diseases or conditions. * receiving specific medication/interventions as specified per protocol.
the real word study of albumin-binding taxol for lung cancer treatment

Conditions: Lung Cancer

Summary: the investigators conduct the real world study to explore the efficacy and safety of albumin-binding taxol in lung cancer .


Eligibility criteria:
inclusion criteria: 1. male or female patients . 2. confirmed by histopathology or cytology of lung cancer 3. patients should be voluntary to the trial and provide with signed informed consent 4. the researchers believe patients can benefit from the study. exclusion criteria: 1. patients with a known history of allergic reactions and/or hypersensitivity attributed to albumin-binding taxol or its accessories 2. pregnant or lactating women 3. patients with albumin-binding taxol contraindications 4. patients of doctors considered unsuitable for the trial

Keywords: albumin-binding taxol
outcome evaluation after fertility preservation

Conditions: Cancer; Fertility Issues

Summary: it is important to evaluate outcomes after different fertility preservation strategies. therefore, this study aims to assess the outcomes after different fertility preservation strategies and identify any factors that may affect their reproductive outcome.

all patients who have undergone or will seek fertility preservation services in pwh will be invited to participate. for those patients who have undergone fertility preservation services in pwh, when they come back to use their frozen gametes or embryos, they will also be invited to participate. medical record assessment when patients come for fertility preservation consultation in pwh, they will be invited to participate. the medical notes of these patients undergoing fertility preservation services will be reviewed. the baseline characteristics including the socio-demographic background, past medical history, details of the surgical procedures, and the subsequent reproductive outcome, will be obtained by reviewing their hospital record. the participants will not be required to take any extra procedures.

Eligibility criteria:
inclusion criteria: * patients aged from 0-50 years old * patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments; * patients seek for fertility preservation services exclusion criteria: -patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
prediction of postoperative visual acuity in cataract patients using a macular optical coherence tomography-based deep learning method

Conditions: Data Collecting

Summary: the purpose of this study is to collect the macular oct images and preoperative and postoperative visual acuity of cataract patients who had been operated in the eye center of the second affiliated hospital of zhejiang university medical college, and to train a model that can relatively accurately predict the postoperative visual acuity of patients by deep learing.


Eligibility criteria:
inclusion criteria: * senile cataract patients, with or without macular disease, the impact of cataract on vision has affected the daily life of patients. exclusion criteria: * glasses can obviously improve eyesight * in addition to macular disease, combined with other eye diseases that seriously affect vision, resulting in no significant improvement in postoperative vision * complicated cataract surgery due to trauma and other reasons * combined with other eye diseases not suitable for intraocular lens implantation * patients with systemic diseases who cannot tolerate surgery

Keywords: artificial intelligence deep learning cataract surgery acuity vision macular optical coherence tomography
multi-country observational study to collect the frequency of sexual dysfunction with antidepressant treatment, either with ssris or duals at 8 weeks and 6 months

Conditions: Major Depressive Disorder

Summary: in usual clinical conditions, depressed patients with no sexual dysfunction, after signing their consent for the dissemination of their clinical information will begin their treatment with any ssri or a dual antidepressant as per the best clinical decision of their treating psychiatrist. sexual dysfunction will be identified along the 6 months of active observation. psychiatrists will decide to change dose, augment, shift or combine antidepressants at their clinical discretion in the benefit of their patients and all clinical decisions will be recorded.comparisons among antidepressants will be made in terms of their sexual dysfunction potentiality.


Eligibility criteria:
inclusion criteria: * meet the criteria for mdd, as defined by the icd-10 or dsm-iv-tr * are at least moderately depressed (baseline cgi-s less than or equal to 4) * provide written consent to the release of their data after being informed about the study * present with an episode of mdd (current, new or first episode) within the normal course of care, and agree to initiate antidepressant therapy with any available ssri or snri class of antidepressant in accordance with the investigator's decision for the management of the patient * have been sexually active in the week prior to enrollment, either with a partner or autoerotic activity exclusion criteria: * meet any of the following criteria for sexual dysfunction at study entry (mcgahuey et all. 2000: asex total score less than or equal 19 or asex score less than or equal to 5 on any item, or asex score less than or equal to 4 on any 3 items * are simultaneously participating in a different study that includes a treatment intervention and/or an investigational drug * have a history of treatment resistant depression (trd) defined as a failure to respond to 2 different antidepressants from different classes after treatment at therapeutic dose for a minimum of 4 weeks * have any previous or current diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder, bipolar disorder, dysthymia, mental retardation, or dementia * have received any antidepressant within 1 week prior to enrollment (1 month prior to enrollment for fluoxetine)
parental attitudes in invitro fertilization

Conditions: Infertility, Female

Summary: the relationship between revelation of mode of conception and child behavior is not known

start of assisted reproductive techniques over the past 25 years made many otherwise infertile couples to become parents to genetically related children.

Eligibility criteria:
inclusion criteria: * parents who were enrolled in icsi and pregnancy occurred exclusion criteria: * icsi with no pregnancy
clinical trial of yiqi wenyang jiedu prescription in the prevention and treatment of postoperative metastasis and recurrence of gastric cancer

Conditions: Gastric Carcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of yiqi wenyang jiedu prescription for postoperative gastric cancer.

this study include a multicenter, randomized, double-blind, placebo, parallel controlled clinical trial.the randomized clinical trial will enroll approximately 212 patients. participants will be randomly divided into experimental (n=106) and control groups (n=106).patients in the experimental group was treated with yiqiuyang jiedu prescription within 6-8 months after radical gastroctomy and after the completion of standard regimen (xelox and sox) for at least 6 cycles of adjuvant chemotherapy. patients in the control group will receive the placebo.the primary endpoint is 2-year dfs (disease-free survival) rate after surgery, that refers to the proportion of patients who do not have recurrence, metastasis or death (from any cause) within 2 years after surgery. the research protocol was approved by the relevant ethics committees, and the study was conducted according to the declaration of helsinki and good clinical practice guidelines. patients gave written informed consent to participate in the trial.

Eligibility criteria:
inclusion criteria: 1. the non-esophagogastric junction gastric cancer of stage ii-iii that met the diagnostic criteria, and no tumor recurrence and metastasis was determined by imaging; 2. within 6-8 months after radical gastrectomy for gastric cancer (r0), adjuvant chemotherapy of standard regimen (xelox and sox) has been completed for at least 6 cycles; 3. ecog score 0-2; 4. 18-75 years old, male or female; 5. the expected survival time is ≥3 months; 6. voluntary participation in the study, signing informed consent, good compliance with follow-up. exclusion criteria: 1. patients with other primary tumors; 2. gastric cancer patients were pathologically diagnosed as adenosquamous carcinoma, with lymphoid stromal carcinoma (medullary carcinoma), hepatoid adenocarcinoma, squamous cell carcinoma, signed-ring cell carcinoma, undifferentiated carcinoma, gastric neuroendocrine tumor, gastric mesenchymal tumor, gastric malignant lymphoma and other gastric malignancies; 3. patients who had previously received preoperative neoadjuvant chemotherapy; 4. patients with past or current targeted drug therapy; 5. patients undergoing previous or ongoing gastric radiotherapy; 6. patients with past or ongoing tumor immunotherapy; 7. mental patients; 8. patients with serious and uncontrolled organic diseases or infections, such as decompensated heart, lung and renal failure, which lead to intolerance of chemotherapy; 9. patients who received clinical trials of small molecule drugs within 28 days or large molecule drugs within 3 months; 10. patients who are known to be allergic or intolerant to the study drug.

Keywords: postoperative gastric cancer yiqi wenyang jiedu prescription chinese herbal medicine randomized controlled trial 2-year disease-free survival rate
efficacy and safety of 500mg of fulvestrant

Conditions: Breast Cancer

Summary: fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. the dose used in studies so far has been well tolerated and may be too low for optimal effectiveness. in this study, a higher dose will be used to see whether an improved outcome will result.

* fulvestrant will be administered by intramuscular injection on day 1, day 15 and day 29 and then every 28 days thereafter. * participants will have a physical examination and blood work performed on each treatment date. after teh study treatment has been completed, the physical examinations will be done every three months for the first 2 years, every 6 months for years 2-5, and annually after 5 years. * participants may remain on study treatment until disease progression or until they experience serious side effects.

Eligibility criteria:
inclusion criteria: * female * 18 years of age or older * histologically confirmed adenocarcinoma of the breast progressing local-regional or metastatic disease that is not considered amenable to curative treatment * evidence of hormone sensitivity of primary or secondary tumor tissue * postmenopausal as defined by criteria listed in protocol * may have had adjuvant endocrine therapy if discontinued at least 12 months prior to inclusion. subjects who have had minimal exposure to adjuvant or first line metastatic endocrine treatment during the 12 months prior to study enrollment can be eligible with overall pi and sponsor permission * prior trastuzumab and biologic therapy is allowed, but must be discontinued more than 2 weeks prior to inclusion * presence of measurable or evaluable, nonmeasurable, disease. any x-rays and scans for assessment of measurable disease must be performed with 28 days prior to registration * eastern cooperative oncology group (ecog) performance status of 0,1 or 2 exclusion criteria: * presence of life-threatening metastatic disease * endocrine therapy the advanced disease setting * systemic chemotherapy, whether as adjuvant therapy or for advanced disease, within previous 4 weeks * trastuzumab or biologic therapy within previous 2 weeks * extensive radiation therapy within the last 2 weeks * prior adjuvant or neoadjuvant treatment with fulvestrant is not allowed * concomitant anticancer treatments * chronic bisphosphonates for hypercalcemia or prevention of bone metastases * subjects receiving long-term anticoagulant therapy with warfarin * estrogen replacement therapy within 6 months of trial entry * previous or current systems malignancy within the past 3 years * treatment with non approved or investigational drug within 2 weeks before study entry * any evidence of severe or uncontrolled systemic disease * history of bleeding diathesis * any severe concomitant condition which makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the study protocol

Keywords: hormone receptor positive breast cancer fulvestrant
evaluation of the diagnostic potential of bay1006578 in probable alzheimers disease patients versus healthy volunteers and radiation dosimetry of bay1006578 in healthy volunteers

Conditions: Diagnostic Imaging

Summary: pet (positron emission tomography) imaging with bay1006578 for investigation of diagnostic potential in probable alzheimer disease patients versus healthy volunteers and radiation dosimetry in healthy volunteers.


Eligibility criteria:
inclusion criteria: * all: * males or females aged \>/- 50 years * participants must be able to understand the information provided on purpose and conduct of the clinical study, must be capable of giving fully informed consent in writing, and have read and signed the informed consent prior to study participation * healthy volunteers for brain imaging: * mini-mental state examination (mmse) score of \>/= 28 * cdr score of zero (0) * patients for brain imaging: * patient fulfills diagnostic and statistical manual of mental disorders (dsm-iv) and national institute of neurological and communicative disorders and stroke, alzheimer's disease and related disorders association (nincds-adrda) criteria for probable alzheimer's disease (ad), which are cognitive deficits such as memory decline and impairment in at least one other cognitive domain (e.g. aphasia, apraxia, agnosia or executive dysfunction) * patient has mild to moderate dementia with a dementia score of \>/= 20 on the mini mental state examination (mmse) / with a clinical dementia rating score of 1 or 2 (cdr) exclusion criteria: * all: * no significant disease or drug use * patients for brain imaging: * evidence for any other neurological or psychiatric disease * healthy volunteers for brain imaging: * family history of alzheimer's disease in a 1st or 2nd degree relative under 75 years of age

Keywords: alzheimer's disease diagnostic imaging pet diagnosis pet tracer
efficacy and safety of intravenous ferric carboxymaltose (fcm) in patients with iron deficiency anemia (ida)

Conditions: Iron Deficiency Anemia

Summary: the main objective of this study is to demonstrate the efficacy and safety of an investigational intravenous (iv) iron, ferric carboxymaltose (fcm), compared to oral iron in subjects who have iron deficiency anemia (ida) and have shown an unsatisfactory response to oral iron.


Eligibility criteria:
inclusion criteria: * male or female subjects ≥ to 18 years of age and able to give informed consent. * diagnosis of iron deficiency anemia (ida). * hemoglobin (hgb) ≤ to 11 g/dl. * ferritin ≤ to 100 ng/ml or ≤ 300 when transferrin saturation (tsat) was ≤ 30%. * must demonstrate an unsatisfactory response or intolerance to oral iron. exclusion criteria: * known hypersensitivity reaction to any component of ferric carboxymaltose or ferrous sulfate. * previously randomized in a clinical study of ferric carboxymaltose (fcm). * requires dialysis for treatment of chronic kidney disease. * no evidence of iron deficiency. * any non-viral infection. * ast or alt at screen 1, as determined by central labs, greater than 1.5 times the upper limit of normal. * known positive hepatitis with evidence of active disease. * received an investigational drug within 30 days of screening. * alcohol or drug abuse within the past 6 months. * hemochromatosis or other iron storage disorders. * estimated life expectancy of less than 6 months or, for cancer patients, an ecog performance status greater than 1. * any other laboratory abnormality, medical condition, or psychiatric disorders which in the opinion of the investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements. * pregnant or sexually-active females who are of childbearing potential and who are not willing to use an acceptable form of contraception.

Keywords: ida
beyond the lung cancer diagnosis: leveraging the oncology clinic setting for actively smoking family members

Conditions: Lung Cancer

Summary: the purpose of this pilot study is to examine, in an innovative setting, the potential for a lung cancer diagnosis in a loved one to represent a teachable moment for smoking cessation in family members or caregivers who are current smokers. the researchers will identify the willingness and preferred modality for smoking cessation among family members/caregivers in this setting. the researchers will estimate abstinence rates at 4, 8, 12, and 24 weeks..


Eligibility criteria:
patient inclusion criteria: 1. patient with newly diagnosed lung cancer within the last 6 months of initial diagnosis/confirmation of diagnosis at the study sites 2. able to provide informed consent 3. able to speak and read english family member/caregiver participant criteria: 1. family member or caregiver (defined as first degree relative \[parent, sibling, child\] or person living in the same household) 2. family member or caregiver must be a current, active smoker (defined as 10 cigarettes per day for 6 consecutive months). 3. at least 18 years of age at time of study consent 4. able to provide informed consent 5. able to speak and read english exclusion criteria: 1. currently receiving formal tobacco dependence treatment- nicotine replacement of any kind, varenicycline or bupropion. 2. medical condition that precludes proposed pharmacotherapy for smoking cessation : recent (≤ 2 weeks) myocardial infarction , history of underlying arrhythmias , history of serious or worsening angina pectoris, pregnancy and breastfeeding

Keywords: lung cancer caregiver
levels of interleukin-6 andtransforming growth factor beta in hcv patients sera

Conditions: Hepatitis C, Chronic

Summary: hepatitis c virus (hcv) infection is associated with significant morbidity and mortality owing to progression of a high percentage (85%) of hcv infected patients to chronic hepatitis, which might lead to the development of liver cirrhosis or hepato cellular carcinoma.. egypt has possibly the highest hcv prevalence in the world, 10-20% of the general population .

currently, second-generation direct-acting antiviral agents have been used for chronic hepatitis c treatment. the association of sofosbuvir with daclatasvir or simeprevir , with or without ribavirin , directly inhibits viral replication . sofosbuvir (400 mg once per day) and daclatasvir (60mg once per day) or simeprevir (150 mg once per day) for 3 months treatment regimens. sofosbuvir-based antiviral therapy guarantees efficacy in hcv eradication in approximately 90% of cases and is associated with mild to moderate adverse effects. overall, studies describe an increase in serum cytokine levels in chronic hepatitis c patients, when compared with healthy individuals. ,interleukin-6(il-6) is produced mainly by kupffer cells and induces the production of the acute phase proteins, c-reactive protein and haptoglobin . previous studies reported that serum interleukin-6 levels were increased, compared with healthy individuals, in patients with some liver diseases.previous results suggest that baseline levels of interleukin, as well as their decrease during treatment .transforming growth factor beta (tgf-β) is a cytokine that has been assigned a key role in epithelial repair. injury to the liver elicits a rapid increase in its expression. hcv -infected hepatocytes produce (tgf-β) which may stimulate t-regulatory cells.

Eligibility criteria:
inclusion criteria: * age from 18 to 70 years. * hcv rna positivity . * any body mass index(bmi). * treatment-naive or treatment experienced. * all fibrosis stages. exclusion criteria: * direct serum bilirubin greater than 2 mg/dl. * serum albumin less than 2.8 g/dl. * international normalization ratio (inr) greater than or equal to 1.7 * platelet count less than 50 000/mm3. * ascites or history of ascites. * hepatic encephalopathy or history of hepatic encephalopathy. * hepatocellular carcinoma. * serum creatinine greater than 2.5 mg/dl . * pregnancy.

Keywords: hepatitis c virus therapy interleukin-6 transforming growth factor -beta sustained virological response
common and differentiated representations between social exclusion and social separation

Conditions: Healthy

Summary: explore the shared or separated neural mechanisms of social exclusion and social segregation and compare differential effects of avp and oxt on these social interaction function.

a large body of research has shown that there are differences in the neural representation between social exclusion and social segregation, but the results are inconsistent, and the exploration of the neural basis is still insufficient. in addition, there are two mainstream theoretical explanations for these differences, namely the construction-level theory and the emotion-based theory, but there is no consistent theoretical model yet. therefore, further exploration is necessary to confirm the cognitive and neural mechanisms underlying the differences between social exclusion and social segregation, and to attempt to reveal the theoretical explanations for these differences. in this project, the investigators propose to perform behavioral and functional magnetic resonance imaging (fmri) techniques to examine the shared or separate neural mechanisms of social exclusion and social segregation (exp 1: social exclusion; exp 2: social separation) and investigate the modulatory effects of oxt/avp on them (plc/24iu oxt/20iu avp).

Eligibility criteria:
inclusion criteria: 1. healthy subjects; 2. without any past or present psychiatric or neurological disorders; 3. without any current psychotherapeutic medication. exclusion criteria: 1. with any past or present psychiatric or neurological disorders; 2. with any current psychotherapeutic medication.

Keywords: social exclusion social separation oxytocin arginine vasopressin fmri